Want to see INO full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.25Last Year’s EPS
-0.61Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial progress on multiple fronts—regulatory milestones (BLA accepted, mid-cycle review with no new issues, PDUFA date set), strong Phase I/II efficacy/safety signals, commercial preparation and advancing partnerships—tempered by material near-term financial constraints (cash declined ~36%, an $18M estimated Q2 burn and runway into only Q1 2027), outstanding regulatory questions about accelerated approval eligibility and an active competitive landscape. Overall the tone was optimistic about the program and platform advancement but realistic about financing and regulatory uncertainties.Company Guidance
Regulatory Progress on INO-3107
BLA for INO-3107 accepted for review under the FDA accelerated approval program (file accepted Dec 2025); PDUFA target date set for October 30, 2026. FDA completed mid-cycle review with no new significant issues and scheduled late-cycle review for Q3 2026. FDA reiterated intent to schedule an informal meeting to discuss accelerated approval eligibility.
Strong Phase I/II Clinical Efficacy and Safety Signals
Phase I/II results showed the vast majority of patients experienced a 50% to 100% reduction in surgeries in year 1 with continued clinical improvement in year 2. Safety profile highlighted as improved versus the comparator, notably not requiring surgery to maintain minimal residual disease during the dosing window.
Commercial Readiness and Product Differentiation
Company completed targeting, segmentation and product positioning; plans to commercialize in the U.S. with support from a contract sales organization and engaged logistics, specialty distributor, specialty pharmacy and patient hub partners. Key operational differentiation versus competitor: no ultra-cold chain and no requirement for surgery during dosing, and positive feedback from physicians and patient community at COSM.
Pipeline Partnerships and Platform Advances
Announced collaboration with Akeso and Dana-Farber to evaluate INO-5412 + dual checkpoint inhibitor in GBM (Phase II adaptive platform). Advanced DPROT platform with preclinical Factor VIII data for hemophilia A and added rare disease targets (Fabry disease, hypophosphatasia) to the pipeline; pursuing partners to accelerate development.
Balance Sheet Strengthened via Equity Offering
Completed underwritten public equity offering in April 2026 with net proceeds of approximately $16 million, extending estimated cash runway into Q1 2027 (beyond the PDUFA date). Cash, cash equivalents and short-term investments at March 31, 2026 were $37.7 million.
Operating Expense Reduction
Operating expenses decreased 13% year-over-year from $25.1 million in Q1 2025 to $21.9 million in Q1 2026, reflecting resource prioritization toward INO-3107.
Per-Share Loss Improved
Reported net loss of $19.7 million in Q1 2026 (same dollar loss as Q1 2025), with loss per share narrowing to $0.28 from $0.51 a year earlier (approximately a 45% improvement in loss per share, driven by share count changes).
INO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.34 | $1.36 | +1.49% |
Mar 12, 2026 | $1.68 | $1.66 | -1.19% |
Nov 10, 2025 | $2.15 | $2.00 | -6.98% |
Aug 12, 2025 | $1.49 | $1.70 | +14.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inovio Pharmaceuticals (INO) report earnings?
Inovio Pharmaceuticals (INO) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Inovio Pharmaceuticals (INO) earnings time?
Inovio Pharmaceuticals (INO) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INO EPS forecast?
INO EPS forecast for the fiscal quarter 2026 (Q2) is -0.25.
